Peptoids: Protease-Resistant Peptide Mimics
Peptoid Engineering
230+ side chains
At least 230 different amines have been used as peptoid side chains, generating chemical diversity impossible with natural amino acids.
Dohm et al., Current Pharmaceutical Design, 2011
Dohm et al., Current Pharmaceutical Design, 2011
View as imagePeptides are among the most potent biological molecules known, but they share a crippling weakness: proteases destroy them within minutes of entering the bloodstream. A 2011 review in Current Pharmaceutical Design described the core problem: "current development of peptide-based pharmaceuticals is hindered by their potential for misfolding and aggregation, and particularly, for rapid in vivo degradation post-administration."[1] Peptoids offer a structural solution to this problem. By moving the side chain from the alpha-carbon to the backbone nitrogen, peptoids become invisible to the enzymes that recognize and cleave natural peptides. This single modification changes proteolytic stability, conformational behavior, cell permeability, and synthetic accessibility. This article covers what peptoids are, how they differ from peptides, where the research stands, and what limitations remain.
Key Takeaways
- Peptoids shift the side chain from the alpha-carbon to the backbone nitrogen, eliminating the protease recognition site while preserving functional diversity (Simon et al., 1992)
- Over 230 commercially available amines can serve as peptoid side chains, creating chemical libraries far cheaper and more diverse than peptide equivalents (Dohm et al., 2011)
- Triazolium-based peptoids showed selective antibacterial activity by disrupting bacterial membranes without damaging eukaryotic cell membranes (De et al., 2025)
- A peptide-peptoid hybrid of alpha-CGRP maintained biological activity while gaining the stability needed for therapeutic use in heart failure models (Kumar et al., 2025)
- Machine learning models can now predict peptide stability in the gastrointestinal tract, accelerating the design of orally bioavailable peptoid-like molecules (Wang et al., 2023)
- No peptoid has yet received FDA approval, though several are in preclinical development for antimicrobial and cardiovascular applications
What Peptoids Are and How They Differ from Peptides
A peptoid is an oligomer of N-substituted glycines. In a natural peptide, the side chain (the R group that distinguishes one amino acid from another) is attached to the alpha-carbon. In a peptoid, that same side chain is attached to the backbone nitrogen instead. The backbone itself remains a repeating amide structure, similar to a peptide, but the shift in side chain attachment has three major consequences.
First, the backbone loses its chirality. Natural amino acids (except glycine) have a chiral center at the alpha-carbon, which forces each residue into specific conformational preferences. Peptoid residues are achiral at the backbone level, which gives them greater conformational freedom but also makes their folding behavior harder to predict and control.
Second, the backbone loses its hydrogen bond donor capacity. In a peptide, the NH group at each amide bond can donate hydrogen bonds, stabilizing secondary structures like alpha-helices and beta-sheets. In a peptoid, the nitrogen carries a side chain instead of a hydrogen, so it cannot donate hydrogen bonds. This fundamentally changes how peptoids fold and interact with biological targets.
Third, proteases cannot recognize the modified backbone. Most proteases identify their substrates by interacting with the NH and the side chain on the alpha-carbon. When the side chain moves to the nitrogen, the protease's recognition site is disrupted. The peptide bond is still there, but the enzyme cannot bind to it properly. This is the basis of peptoid protease resistance.
For how other backbone modifications achieve similar goals, see Beta-Peptides and Gamma-Peptides: Beyond Natural Amino Acid Backbones and D-Amino Acid Peptides: Mirror-Image Molecules That Resist Degradation.
The Protease Problem That Peptoids Solve
Proteases are the immune system's quality control officers for the bloodstream. They break down foreign proteins and spent signaling peptides within minutes. This is useful for biology but devastating for peptide drugs. A therapeutic peptide injected intravenously may have a half-life measured in single-digit minutes before proteases reduce it to inactive fragments.
This creates a pharmaceutical paradox: peptides are exquisitely selective for their targets (often 10 to 100 times more so than small molecule drugs for the same receptor), but they are destroyed before they can reach those targets in sufficient concentration. The result is that most peptide drugs require frequent injections, often multiple times daily, and oral delivery remains nearly impossible for unmodified peptides because gastrointestinal proteases are even more aggressive than blood proteases.
A 2023 study used machine learning to predict peptide stability in the gastrointestinal tract, training models on empirical degradation data. The work revealed that specific sequence motifs and structural features determined whether a peptide survived transit through the stomach and intestines.[2] Peptoids bypass this entire problem by being structurally invisible to the proteases that degrade natural peptides.
Multiple strategies exist for improving peptide stability. Cyclization constrains the backbone to prevent protease access. Stapled peptides lock helical conformations in place. D-amino acid substitution creates mirror-image bonds that proteases cannot cleave. A 2025 study demonstrated that hydrocarbon stapling of the antimicrobial peptide ocellatin-3N improved its proteolytic stability while also enhancing antibacterial potency.[3] A separate 2026 study showed that combining cyclization with stereochemical inversion (D-amino acids) in a beta-turn antimicrobial peptide produced a molecule resistant to both trypsin and chymotrypsin while retaining activity against multidrug-resistant bacteria.[4]
Peptoids represent the most radical version of this approach: rather than modifying specific residues, they change the entire backbone architecture. Where other strategies make surgical modifications to a peptide (replacing a few amino acids, adding a chemical staple, closing a ring), peptoids rebuild the backbone itself. Every residue is modified. Every amide nitrogen carries a side chain instead of a hydrogen. The result is a molecule that looks and acts like a peptide from a distance, but up close is unrecognizable to the enzymes that evolved to degrade peptides.
How Peptoids Are Made: Submonomer Synthesis
One of peptoids' most practical advantages is their synthesis. Natural peptides are typically made by solid-phase peptide synthesis (SPPS), where each amino acid is added as a pre-formed, protected monomer. This is effective but expensive, because each amino acid monomer must be individually synthesized, purified, and protected.
Peptoids use a submonomer approach. Each residue is installed in two chemical steps: first, an acylation step adds a haloacetic acid to the growing chain; second, a displacement step uses a primary amine to introduce the side chain. Because any primary amine can serve as the side chain source, the chemical diversity available to peptoid designers vastly exceeds what is possible with the 20 natural amino acids.
A 2011 review documented that at least 230 different amines had already been used as peptoid side chains, drawn from the thousands of commercially available primary amines.[1] This means peptoid libraries can be generated at a fraction of the cost of equivalent peptide libraries, with far greater chemical diversity at each position. The submonomer method also avoids the racemization problems that plague some peptide synthesis approaches, since the backbone positions are achiral.
The practical implications of this synthesis are substantial. A research group can generate a library of hundreds of peptoid variants in days using automated synthesizers, screen them against a biological target, and identify leads at a pace that peptide chemistry cannot match. The cost per compound is lower because the starting materials (primary amines) are commodity chemicals rather than specialty amino acid derivatives. This combination of speed, diversity, and cost has made peptoids a preferred platform for combinatorial library approaches.
For how library-based approaches work in peptide drug discovery, see Combinatorial Peptide Libraries: The Shotgun Approach to Drug Discovery.
Antimicrobial Peptoids: The Leading Application
Antimicrobial activity is the most developed application area for peptoids. Natural antimicrobial peptides (AMPs) are effective at killing bacteria by disrupting their cell membranes, but their rapid proteolytic degradation limits their clinical utility. Peptoids can mimic the amphipathic structure of AMPs (cationic and hydrophobic regions) while resisting the proteases that destroy their natural counterparts.
A 2025 study in the Journal of Medicinal Chemistry investigated triazolium-based peptoids designed to mimic host defense peptides. Using biophysical methods with lipid bilayers, the researchers demonstrated that these peptoids selectively disrupted bacterial membranes (modeled by anionic phospholipids) while leaving eukaryotic membranes (modeled by neutral phospholipids) intact.[5] This selectivity is critical: an antimicrobial agent that destroys all cell membranes indiscriminately is toxic. The ability of these peptoids to discriminate between bacterial and human membranes based on lipid composition is a prerequisite for therapeutic development.
A 2024 study explored a related strategy: substituting lysine residues with lysine homologues (modified side chains with different chain lengths) to tune both antimicrobial activity and proteolytic stability simultaneously.[6] The work showed that small changes in side chain length affected membrane interaction and enzyme recognition independently, suggesting fine-tuned optimization is possible.
A 2026 study took a different approach entirely, using fragment-based display on small-molecule scaffolds to generate antibacterial peptidomimetics. Rather than mimicking the full peptide backbone, this strategy captured the pharmacophoric features of antimicrobial peptides on a drug-like scaffold.[7]
The antimicrobial peptoid field is converging on a design principle: amphipathicity matters more than specific sequence. Unlike natural antimicrobial peptides, where activity often depends on a precise arrangement of cationic and hydrophobic residues in a helical structure, peptoids achieve similar membrane disruption through a broader range of conformations. This flexibility in design space makes it easier to optimize for selectivity (killing bacteria while sparing human cells), potency (effective at low concentrations), and stability (resistance to degradation in biological fluids) simultaneously.
For broader context on antimicrobial peptide research, see Antimicrobial Peptides as Alternatives to Antibiotics: Can They Solve Resistance?.
Peptoid Hybrids: Combining Peptide and Peptoid Features
Pure peptoids sacrifice one of peptides' key advantages: the ability to fold into defined three-dimensional structures through backbone hydrogen bonding. This matters because many biological targets require a ligand with a specific shape to bind effectively. Peptoid-peptide hybrids attempt to capture the best of both worlds: peptide-like folding at positions where structure matters, with peptoid residues at positions where protease resistance matters.
Two 2025 studies from the same research group demonstrated this approach with alpha-calcitonin gene-related peptide (alpha-CGRP), a cardioprotective neuropeptide with poor bioavailability. The group created a peptide-peptoid hybrid by replacing select residues with peptoid equivalents while preserving the residues critical for receptor binding. The hybrid maintained biological activity while gaining the stability needed for therapeutic evaluation.
In one study, the hybrid ameliorated cardiac remodeling in a pressure overload-induced heart failure model in mice.[8] In a companion study published in Frontiers in Pharmacology, the same hybrid protected against heart failure by preserving cardiac function markers that declined in untreated animals.[9] These studies illustrate the hybrid strategy: not all positions in a peptide need to be proteolytically stable, only the positions that proteases target. By identifying those positions and selectively replacing them with peptoid residues, the resulting hybrid retains function while gaining durability.
The hybrid approach also addresses a limitation of pure peptoids in receptor binding. Most biological receptors evolved to recognize peptide backbones, including the NH hydrogen bond donors that peptoids lack. A hybrid molecule preserves these critical interactions at the binding interface while making the non-binding portions resistant to degradation. This is analogous to how engineers reinforce only the load-bearing portions of a structure rather than armoring the entire building. The CGRP hybrid data suggests this targeted approach may be more pharmaceutically tractable than trying to optimize a pure peptoid for tight receptor binding.
Comparing Strategies for Protease Resistance
Peptoids are one of several approaches to the protease problem. Each has distinct trade-offs:
| Strategy | Mechanism | Protease Resistance | Structural Impact | Synthesis Cost |
|---|---|---|---|---|
| Peptoids | Side chain on nitrogen | Complete (backbone invisible) | Loses H-bond donors, increased flexibility | Low (submonomer) |
| D-Amino acids | Mirror-image chirality | High (stereospecific recognition disrupted) | Minimal at isolated positions | Moderate |
| Cyclization | Constrained backbone | Moderate-high (reduced conformational access) | Locks shape, limits flexibility | Moderate |
| Stapled peptides | Hydrocarbon cross-links | Moderate (protects local region) | Enforces helical structure | High |
| Beta-peptides | Extra carbon in backbone | Complete (unrecognized backbone) | Different folding patterns (e.g., 14-helix) | High |
| Peptoid-peptide hybrids | Selective N-substitution | Targeted (at modified positions) | Partially preserved | Moderate |
For detailed coverage of each approach, see Cyclic vs Linear Peptides: Why Shape Matters for Function, Stapled Peptides: Locking Peptides into Helical Shapes for Drug Design, and Peptidomimetics: Molecules That Mimic Peptides but Aren't.
A 2025 study on spider venom peptides illustrated how proteolytic stabilization can unlock oral bioavailability. The researchers stabilized the insecticidal peptide U1-AGTX-Ta1b against gastrointestinal proteases, converting it from an injectable-only compound to an orally active bioinsecticide.[10] While this study used modifications other than peptoid substitution, it demonstrates the general principle: protease resistance is the gateway to oral delivery, regardless of which specific strategy achieves it.
Peptoids in Drug Discovery: Current Status
Despite three decades of research since the original 1992 publication by Simon, Zuckermann, and Bartlett, no peptoid has received FDA approval. Several factors explain this gap.
Target affinity. Peptoids' conformational flexibility is a double-edged sword. While it enables them to adopt many shapes, it also means they do not pre-organize into the precise conformation needed to bind a protein target. Peptides benefit from their folding tendencies; a helical peptide arrives at its receptor already in the right shape. A peptoid must find the right shape from a larger conformational ensemble, which typically means lower binding affinity.
Pharmacokinetic unknowns. Protease resistance does not automatically translate to good pharmacokinetics. Peptoids must still be absorbed across biological membranes, distributed to target tissues through the bloodstream, metabolized by non-proteolytic pathways (such as oxidation or conjugation in the liver), and eventually cleared from the body through the kidneys or bile. Each of these processes has been studied in far less detail for peptoids than for small molecules or antibodies. The few pharmacokinetic studies that exist suggest peptoids have better plasma stability than peptides but variable tissue distribution.
Competition from other approaches. GLP-1 receptor agonists (semaglutide, tirzepatide) achieved oral bioavailability through different strategies: fatty acid conjugation and permeation enhancers. Antibody-drug conjugates offer another path. The pharmaceutical industry has invested heavily in these approaches, leaving fewer resources for peptoid development.
A 2022 study described a rational strategy for designing peptidomimetic small molecules based on cyclic peptide structures, illustrating how the field is converging toward hybrid approaches that combine peptoid-like stability with small-molecule-like pharmacology.[11]
A 2026 review examined non-ribosomal peptide engineering as another route to creating novel antimicrobial compounds, noting that bacterial biosynthetic machinery naturally incorporates non-standard amino acids and backbone modifications that overlap with peptoid chemistry.[12]
Limitations of the Peptoid Approach
Peptoids solve the protease problem but introduce new ones:
Reduced target affinity. The loss of backbone hydrogen bond donors means peptoids cannot form the same secondary structures as peptides. Many protein-protein interactions depend on recognizing helical or sheet-like peptide conformations. Peptoids must compensate for this loss through side chain interactions alone.
Conformational heterogeneity. Peptoids are more flexible than peptides, which means they exist as mixtures of conformations in solution. This reduces the fraction of molecules in the "active" conformation at any given time, effectively diluting potency.
Limited folding predictability. Decades of research have produced reliable tools for predicting how a peptide sequence will fold. Peptoid folding is less well understood. Bulky side chains can force local conformational preferences (the "peptoid helix"), but predicting the three-dimensional structure of a longer peptoid from its sequence remains difficult.
Clearance and accumulation. Protease resistance means peptoids persist longer in the body. This is desirable for efficacy but raises questions about accumulation, particularly in the kidneys and liver. Long-term toxicity data for most peptoid scaffolds is sparse.
Intellectual property. The general peptoid concept is not patentable (it was published in 1992). Specific peptoid sequences can be patented, but the broad platform is available to anyone. This has limited pharmaceutical company investment in the platform.
Where Peptoid Research Is Heading
Three trends are shaping the next decade of peptoid development.
Hybrid architectures. Rather than pure peptoids or pure peptides, the field is increasingly exploring chimeric molecules that strategically place peptoid residues at protease-vulnerable positions while retaining peptide residues at positions critical for target binding. The CGRP hybrid work demonstrates that this approach can preserve bioactivity while gaining stability. As more structure-activity data accumulates, researchers can make increasingly informed decisions about which positions to modify.
Computational design. Machine learning models that predict peptide stability are beginning to incorporate peptoid features. As training datasets expand to include peptoid degradation data alongside peptide data, it will become possible to computationally design peptoid sequences optimized for stability, target affinity, and selectivity before synthesizing a single molecule. The 2023 study on GI tract stability prediction is an early step in this direction.[2]
Materials science applications. Peptoids are finding uses outside of drug development. Their defined structures and tunable properties make them candidates for self-assembling nanomaterials, catalysts, and diagnostic sensors. In these applications, the lack of target affinity that limits drug development is irrelevant, and the chemical diversity and stability of peptoids become pure advantages.
The absence of an FDA-approved peptoid drug after 30 years of research is not a failure of the chemistry but a reflection of the drug development landscape. Peptoids solve the protease problem convincingly. The remaining challenges (target affinity, pharmacokinetics, and economic incentives) are shared across the entire peptidomimetics field, not unique to peptoids.
For how computational methods are addressing some of these design challenges, see De Novo Peptide Design: Building Drugs from Scratch with Computers.
The Bottom Line
Peptoids represent one of the most elegant solutions to the protease degradation problem that limits peptide therapeutics. By shifting the side chain from the alpha-carbon to the backbone nitrogen, they become invisible to proteolytic enzymes while retaining the ability to display diverse chemical functionality. Antimicrobial applications lead the field, with selective membrane disruption demonstrated in recent studies. Peptide-peptoid hybrids offer a promising middle path that preserves biological activity while gaining stability. Three decades after their invention, peptoids remain a platform with substantial potential and no approved drugs, a gap that reflects both real limitations and structural barriers to pharmaceutical investment.